ES2943711T3 - Agentes anticancerígenos y preparación de estos - Google Patents

Agentes anticancerígenos y preparación de estos Download PDF

Info

Publication number
ES2943711T3
ES2943711T3 ES14863201T ES14863201T ES2943711T3 ES 2943711 T3 ES2943711 T3 ES 2943711T3 ES 14863201 T ES14863201 T ES 14863201T ES 14863201 T ES14863201 T ES 14863201T ES 2943711 T3 ES2943711 T3 ES 2943711T3
Authority
ES
Spain
Prior art keywords
compound
compounds
formula
group
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14863201T
Other languages
English (en)
Spanish (es)
Inventor
Arun K Ghosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of ES2943711T3 publication Critical patent/ES2943711T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES14863201T 2013-11-19 2014-11-19 Agentes anticancerígenos y preparación de estos Active ES2943711T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361906133P 2013-11-19 2013-11-19
PCT/US2014/066458 WO2015077370A1 (en) 2013-11-19 2014-11-19 Anti-cancer agents and preparation thereof

Publications (1)

Publication Number Publication Date
ES2943711T3 true ES2943711T3 (es) 2023-06-15

Family

ID=53180106

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14863201T Active ES2943711T3 (es) 2013-11-19 2014-11-19 Agentes anticancerígenos y preparación de estos

Country Status (20)

Country Link
US (1) US10000505B2 (OSRAM)
EP (1) EP3071563B1 (OSRAM)
JP (2) JP6937578B2 (OSRAM)
KR (1) KR102428737B1 (OSRAM)
CN (3) CN113773333A (OSRAM)
AU (1) AU2014353087B2 (OSRAM)
BR (1) BR112016011430B1 (OSRAM)
CA (1) CA2931111C (OSRAM)
CL (1) CL2016001209A1 (OSRAM)
DK (1) DK3071563T3 (OSRAM)
EA (1) EA035262B1 (OSRAM)
ES (1) ES2943711T3 (OSRAM)
FI (1) FI3071563T3 (OSRAM)
IL (2) IL282430B2 (OSRAM)
MX (1) MX375896B (OSRAM)
MY (1) MY189459A (OSRAM)
PE (1) PE20161240A1 (OSRAM)
PH (2) PH12021551085A1 (OSRAM)
PT (1) PT3071563T (OSRAM)
WO (1) WO2015077370A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3071563B1 (en) * 2013-11-19 2023-04-19 Purdue Research Foundation Anti-cancer agents and preparation thereof
US11584754B2 (en) 2016-06-08 2023-02-21 William Marsh Rice University Derivatives of thailanstatin A, methods of treatment and methods of synthesis thereof
RU2019111768A (ru) 2016-09-23 2020-10-23 Пердью Ресерч Фаундейшн Противораковые агенты и их получение
US10301319B2 (en) 2017-09-20 2019-05-28 Ph Pharma Co., Ltd. Thailanstatin analogs
CN109020876A (zh) * 2018-09-21 2018-12-18 大连理工大学 一种新型6-羟基-2h-二氢吡啶-3-酮的制备方法
PE20211473A1 (es) 2018-12-13 2021-08-05 Eisai Randd Man Co Ltd Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso
EP4132934A1 (en) * 2020-04-09 2023-02-15 Bristol-Myers Squibb Company Meayamycin analogues and methods of use
CN113563361B (zh) * 2021-08-17 2022-05-20 浙江珲达生物科技有限公司 一种从伯克霍尔德菌发酵液提取fr901464的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
US7825267B2 (en) 2006-09-08 2010-11-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
AR080234A1 (es) * 2010-02-25 2012-03-21 Marrone Bio Innovations Inc Cepa bacteriana aislada del genero burkholderia y metabolitos pesticidas del mismo
WO2013032693A2 (en) * 2011-08-27 2013-03-07 Marrone Bio Innovations, Inc. Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom-formulations and uses
ES2656298T3 (es) * 2012-11-05 2018-02-26 Pfizer Inc. Análogos de ayustoestatina
EP3071563B1 (en) 2013-11-19 2023-04-19 Purdue Research Foundation Anti-cancer agents and preparation thereof

Also Published As

Publication number Publication date
CA2931111A1 (en) 2015-05-28
AU2014353087A1 (en) 2016-06-30
CN105829299A (zh) 2016-08-03
CA2931111C (en) 2022-03-15
JP6937578B2 (ja) 2021-09-22
PE20161240A1 (es) 2016-11-27
KR20160086411A (ko) 2016-07-19
IL282430A (en) 2021-06-30
IL282430B2 (en) 2025-04-01
BR112016011430A2 (pt) 2017-09-12
PH12021551085A1 (en) 2023-07-17
IL245637A0 (en) 2016-06-30
CL2016001209A1 (es) 2017-06-02
JP6929903B2 (ja) 2021-09-01
NZ721152A (en) 2022-03-25
US20160297831A1 (en) 2016-10-13
MX2016006591A (es) 2017-05-30
EA201691010A1 (ru) 2016-11-30
BR112016011430B1 (pt) 2022-09-13
PH12016500924A1 (en) 2016-07-18
FI3071563T3 (fi) 2023-05-29
NZ759166A (en) 2022-03-25
AU2014353087B2 (en) 2018-07-19
US10000505B2 (en) 2018-06-19
IL282430B1 (en) 2024-12-01
MY189459A (en) 2022-02-14
MX375896B (es) 2025-03-07
JP2017503753A (ja) 2017-02-02
IL245637B (en) 2021-05-31
WO2015077370A1 (en) 2015-05-28
JP2019189644A (ja) 2019-10-31
CN113461705A (zh) 2021-10-01
CN113773333A (zh) 2021-12-10
EP3071563A4 (en) 2017-09-06
PT3071563T (pt) 2023-05-09
DK3071563T3 (da) 2023-05-08
EP3071563A1 (en) 2016-09-28
EA035262B1 (ru) 2020-05-21
EP3071563B1 (en) 2023-04-19
KR102428737B1 (ko) 2022-08-02

Similar Documents

Publication Publication Date Title
EP3071563B1 (en) Anti-cancer agents and preparation thereof
JP7089061B2 (ja) サイクリン依存性キナーゼ阻害剤としての2-アミノ-ピリジンまたは2-アミノ-ピリミジン誘導体
RU2537319C2 (ru) Способы изготовления и назначение деривата sphaelactone и его композитные лекарства
CN109665968A (zh) 并环化合物及其制备方法和用途
KR20170102885A (ko) 삼환성 스피로 화합물
US12435071B2 (en) Bryostatin compounds and methods of preparing the same
JP2020525409A (ja) 置換アリールエーテル系化合物、その調製方法、医薬組成物およびその応用
JP2024164181A (ja) カリスポンジオリド、その類似体、およびそれらの使用
AU2017277786A1 (en) Derivatives of Thailanstatin A, methods of treatment and methods of synthesis thereof
KR20140048113A (ko) 탁산 및 아베오-탁산 유사체
JP5123429B2 (ja) インドリン抗癌剤
HK40062614A (en) Anti-cancer agents and preparation thereof
NZ721152B2 (en) Anti-cancer agents and preparation thereof
HK1227866B (en) Anti-cancer agents and preparation thereof
HK1227866A1 (en) Anti-cancer agents and preparation thereof
NZ759166B2 (en) Anti-cancer agents and preparation thereof